Cargando…

Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation

Buprenorphine has pharmacologic advantages over methadone, especially buprenorphine’s better safety profile. The true significance of buprenorphine’s introduction lies in returning the care of those suffering from opioid use disorder (OUD) to the hands of the physician. The clinical success of bupre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ling, Walter, Shoptaw, Steve, Goodman-Meza, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889966/ https://www.ncbi.nlm.nih.gov/pubmed/31819701 http://dx.doi.org/10.2147/SAR.S155843

Ejemplares similares

Depot Buprenorphine Injection in the Management of Opioid Use Disorder: From Development to Implementation [Corrigendum]
Publicado: (2020)

Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences
por: Neale, Joanne, et al.
Publicado: (2019)

Sharp decline in hospital and emergency department initiated buprenorphine for opioid use disorder during COVID-19 state of emergency in California
por: Herring, Andrew A., et al.
Publicado: (2021)

Evaluation of the Effects of a Monthly Buprenorphine Depot Subcutaneous Injection on QT Interval During Treatment for Opioid Use Disorder
por: Schmith, Virginia D., et al.
Publicado: (2019)

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis
por: Andorn, Anne C., et al.
Publicado: (2020)

Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings
por: Dunlop, Adrian J., et al.
Publicado: (2021)

Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials
por: Jones, Aksana K., et al.
Publicado: (2020)

Patient perspectives on depot buprenorphine treatment for opioid addiction – a qualitative interview study
por: Johnson, Björn, et al.
Publicado: (2022)

Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder
por: Björnsson, Marcus, et al.
Publicado: (2023)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model
por: Ling, R., et al.
Publicado: (2022)

Novel forms of injectable buprenorphine and French model of opioid use disorder treatment
por: Lapeyre-Mestre, Maryse
Publicado: (2020)

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study
por: Larance, Briony, et al.
Publicado: (2020)

Implementation Facilitation to Promote Emergency Department–Initiated Buprenorphine for Opioid Use Disorder
por: D’Onofrio, Gail, et al.
Publicado: (2023)

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
por: De Aquino, Joao P., et al.
Publicado: (2021)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder
por: Frost, Michael, et al.
Publicado: (2019)

Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia
por: Larance, Briony, et al.
Publicado: (2020)

Personalized Care in Opioid Use Disorder maintained on Buprenorphine
por: Elarabi, H., et al.
Publicado: (2022)

Inpatient Buprenorphine Induction for Opioid Use Disorder in Pregnancy
por: Tavakoli, Amin, et al.
Publicado: (2023)

Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges
por: Arunogiri, Shalini, et al.
Publicado: (2021)

Addiction Recovery Among Opioid-Dependent Patients Treated With Injectable Subcutaneous Depot Buprenorphine: Study Protocol of a Non-randomized Prospective Observational Study (ARIDE)
por: Schulte, Bernd, et al.
Publicado: (2020)

Implementation of emergency department–initiated buprenorphine for opioid use disorder in a rural southern state
por: Bogan, Carolyn, et al.
Publicado: (2020)

Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period
por: Lembke, Anna, et al.
Publicado: (2019)

Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine
por: Gilman, Mark, et al.
Publicado: (2018)

Design and in vivo evaluation of a microparticulate depot formulation of buprenorphine for veterinary use
por: Schreiner, Viktoria, et al.
Publicado: (2020)

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
por: Greenwald, Mark K., et al.
Publicado: (2023)

A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder
por: Seguí, Hemanuel Arroyo, et al.
Publicado: (2020)

Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder
por: Reed, Megan K, et al.
Publicado: (2022)

Pharmacy Availability of Buprenorphine for Opioid Use Disorder Treatment in the US
por: Weiner, Scott G., et al.
Publicado: (2023)

Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review
por: Spreen, Lauren A., et al.
Publicado: (2022)

Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic
por: Currie, Janet M., et al.
Publicado: (2021)

History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder
por: Heidbreder, Christian, et al.
Publicado: (2023)

New developments in the management of opioid dependence: focus on sublingual buprenorphine–naloxone
por: Soyka, Michael
Publicado: (2015)

Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements
por: Phillips-Jackson, Helen, et al.
Publicado: (2020)

Injection Site Reaction to Extended-Release Buprenorphine (Sublocade(®)) for Opioid Use Disorder Fourteen Days after Administration
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine
por: Noble, Florence, et al.
Publicado: (2019)

Opioid Substitution Treatment Using Buprenorphine for Management of Dependence on Natural Opioids: Case Series
por: Kathiresan, Preethy, et al.
Publicado: (2019)

Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder
por: Weintraub, Eric, et al.
Publicado: (2021)

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder
por: Laffont, Celine M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2njp9k7rg9e9d90kb07pse6ss2